Incanthera PLC (AQSE:INC), a company specialising in oncology and dermatology technologies, has appointed John Howes as an independent director, effective immediately.
Following Howes' recruitment, Incanthera's shares will begin trading on the Apex segment of the AQSE Growth Market.
Apex is reserved for larger, more established businesses with a proven growth strategy and which meet high standards of corporate governance.
"This move to the Apex segment is recognition of the commitment of the team to evolve Incanthera into a commercial player on a global stage with the vast opportunities and publicity that brings," said Incanthera Chair Tim McCarthy.
Howes, meanwhile, brings over 43 years of experience in the UK equity capital markets, with expertise in the small and mid-cap sectors.
His previous roles include partner at Matrix Corporate Capital and senior positions at Seymour Pierce, Panmure Gordon, Northland Capital, and Stanford Capital.
"John is well known to the Incanthera team, having been previously in an external advisory capacity to the company for many years including at the time of our flotation on Aquis Stock Exchange in 2020," said McCarthy.